August 14, 2025 – Afternoon Update
San Francisco/Bangalore, August 2025 – SetPoint Medical, a leading medical technology company specializing in bioelectronic medicine, has successfully closed a $140 million funding round to advance its innovative treatment for rheumatoid arthritis (RA). The investment will accelerate clinical trials, expand manufacturing capabilities, and support global commercialization efforts for its pioneering therapy.
SetPoint Medical’s approach leverages implantable neuromodulation devices designed to modulate the body’s immune response, offering a potentially transformative alternative to conventional pharmacological treatments. Unlike traditional therapies, which rely on systemic immunosuppressants, SetPoint’s technology targets the inflammatory pathways at the nerve level, reducing side effects and improving patient outcomes.
The latest funding round was led by prominent global healthcare investors, including OrbiMed, New Leaf Ventures, and Canaan Partners, with participation from strategic life sciences funds. “This investment is a strong vote of confidence in our vision to redefine how autoimmune diseases are treated,” said Dr. Chris Nast, CEO of SetPoint Medical. “We are committed to bringing a safe, effective, and scalable solution to patients who continue to face limitations with current RA therapies.”
Rheumatoid arthritis affects over 20 million people globally, causing chronic pain, joint damage, and reduced mobility. Despite advances in biologics and small-molecule drugs, a significant proportion of patients remain inadequately treated or experience severe side effects. SetPoint Medical’s therapy has the potential to fill this unmet need by offering a targeted, device-based solution that works alongside or independently of traditional medication.
Industry analysts note that the bioelectronic medicine sector is rapidly expanding, with a growing focus on neuromodulation to treat chronic inflammatory and autoimmune conditions. SetPoint Medical’s breakthrough technology positions it as a frontrunner in this emerging field, with the potential to disrupt conventional RA treatment paradigms.SetPoint Medical, a leading medical technology company specializing in bioelectronic medicine, has successfully closed a $140 million funding round to advance its innovative treatment for rheumatoid arthritis (RA). The investment will accelerate clinical trials, expand manufacturing capabilities, and support global commercialization efforts for its pioneering therapy.
The company plans to use the $140 million to complete pivotal trials, secure regulatory approvals in multiple regions, and scale commercial operations. With this funding, SetPoint Medical is poised to transform the lives of millions of RA patients worldwide and establish itself as a leader in next-generation medical therapies
The company’s innovative approach represents a major advancement in treating autoimmune conditions, moving beyond traditional pharmaceutical interventions. This funding milestone demonstrates continued strong investor confidence in medical technology startups that are bringing FDA-approved solutions to market.
The funding round positions SetPoint Medical at the forefront of the biotech sector’s current boom, which has seen remarkable activity across neurotherapies, rare disease treatments, and breakthrough medical devices throughout August 2025.
This announcement comes as part of a broader trend of substantial funding flowing into healthcare technology companies, with investors showing particular interest in startups that have already secured regulatory approval and are ready for commercial deployment.
The medical technology sector continues to attract significant venture capital investment, reflecting the growing demand for innovative healthcare solutions and the potential for substantial returns on breakthrough treatments that address large patient populations.SetPoint Medical, a leading medical technology company specializing in bioelectronic medicine, has successfully closed a $140 million funding round to advance its innovative treatment for rheumatoid arthritis (RA). The investment will accelerate clinical trials, expand manufacturing capabilities, and support global commercialization efforts for its pioneering therapy.
What This Means: SetPoint Medical’s successful funding round signals robust investor appetite for proven medical technologies, particularly those targeting major chronic conditions affecting millions of patients worldwide.
Stay tuned for more startup funding updates as we continue tracking the latest developments in the tech and healthcare sectors.
